Opendata, web and dolomites

PICSOHF SIGNED

PICSOHF, A minimally invasive cardiac intervention medical device to regenerate a damaged heart and extend the life of patients with Heart Failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PICSOHF project word cloud

Explore the words cloud of the PICSOHF project. It provides you a very rough idea of what is the project "PICSOHF" about.

heart    regeneration    hf    follow    cardiac    patients    medium    last    significantly    feedback    sustainability    life    europe    catheter    technological    myocardial    expectations    treatment    impoverished    proof    launch    partial    acute    clinical    cellular    improvements    co    live    recovery    regain    attack    market    elevates    profits    progressive    national    therapy    minutes    intervention    commercial    worldwide    frequent    66m    greatest    proprietary    picsohf    patient    percutaneous    consists    changing    morbidities    reference    function    threatens    clinically    efficacy    picso    discredited    versus    despite    quality    million    biomarkers    regenerate    regenerative    expectancy    prognosis    temporarily    survival    full    right    damaged    demonstrated    tested    miracor    ed    re    innate    solutions    treatments    continuous    people    breakthrough    therapies    hospitalisations    healthcare    stop    26    strategic    hope    unable    once    met    patented    treating    veins    chronic    pattern    changed    device    tissue    software    burden    pressure    controls    reactivating    22    scientific   

Project "PICSOHF" data sheet

The following table provides information about the project.

Coordinator
MIRACOR MEDICAL 

Organization address
address: RUE DE BRUXELLES 174, E40 BUSINESS
city: AWANS
postcode: 4340
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MIRACOR MEDICAL BE (AWANS) coordinator 50˙000.00

Map

 Project objective

Worldwide 26 million people live with HF (Heart Failure) which is a major burden, not only for the patient, but one that also threatens the sustainability of national healthcare systems. Despite advances in treatment solutions over the last 30 years, improvements have not met the expectations for cardiac recovery and prognosis following heart attack. Current treatments are only partial solutions as they cannot regenerate the damaged heart tissue, and are thus unable to stop the progressive loss of heart function, low short- and medium-term life expectancy, and impoverished quality of life due to co-morbidities and/or frequent and continuous re-hospitalisations. Regenerative concepts, such as cellular therapies to regain cardiac function, once of the greatest hope for heart failure patients, have been recently discredited as they have been unable to show scientific proof of efficacy. Miracor, developed and clinically tested PiCSO, a breakthrough cardiac intervention triggering myocardial regeneration. Our therapy consists of a percutaneous right heart catheter intervention using proprietary software for feedback control that temporarily elevates the pressure in cardiac veins reactivating innate regeneration pathways. We have tested PiCSO in chronic HF patients (8 patients versus 22 controls) and demonstrated that 30 minutes of intervention changed the pattern of regenerative biomarkers in cardiac veins that resulted in significantly improved survival at 10 years follow up. Our patented technology (PiCSOHF ) is changing the market in HF, as no similar device is currently available. Our strategic goal is to become Europe´s leading reference in treating HF. After full technological, clinical and commercial development, PICSOHF profits will increase by €66M within 5 years after commercial launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICSOHF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICSOHF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LiCrete (2018)

LiCrete - Light transmitting composite material for building purposes

Read More